莫西沙星联合特布他林对慢性阻塞性肺疾病患者临床疗效及FEV_(1)、FVC、FEV_(1)/FVC的影响  

Effect of moxifloxacin combined with terbutaline on clinical efficacy and FEV_(1),FVC and FEV_(1)/FVC in patients with COPD

作　　者：彭宁[1] 寿志南[1] 陈敏[1] PENG Ning;SHOU Zhi-nan;CHEN Min(Department of Respiratory Medicine,Guiyang First People's Hospital,550002)

机构地区：[1]贵州省贵阳市第一人民医院呼吸内科,贵州贵阳550002

出　　处：《吉林医学》2021年第8期1842-1845,共4页Jilin Medical Journal

摘　　要：目的:探讨莫西沙星联合特布他林对慢性阻塞性肺疾病(简称慢阻肺)患者临床疗效及FEV_(1)、FVC、FEV_(1)/FVC的影响。方法:选取2018年1月~2020年6月慢性阻塞性肺疾病患者82例,根据使用药物的不同分为两组,对照组应用莫西沙星治疗,研究组在对照组治疗基础上联合应用特布他林治疗。比较两组慢阻肺患者临床疗效、FEV_(1)、FVC、FEV_(1)/FVC的影响、不良反应、生活质量评分、血气分析指标、血清PCT水平。结果:研究组临床疗效好于对照组,差异有统计学意义(P<0.05);研究组FEV_(1)、FEV_(1)/FVC、FVC均高于对照组,差异有统计学意义(P<0.05);研究组失眠、皮肤瘙痒、恶心等不良反应发生率低于对照组,差异有统计学意义(P<0.05);研究组活动受限、临床症状、疾病影响均低于对照组,差异有统计学意义(P<0.05);研究组SaO_(2)、PaO_(2)高于对照组,差异有统计学意义(P<0.05),PaCO_(2)低于对照组,差异有统计学意义(P<0.05);研究组血清PCT水平低于对照组,差异有统计学意义(P<0.05)。结论:对慢阻肺患者治疗过程当中,莫西沙星联合特布他林治疗不仅可以有效提高临床疗效,还可以改善患者FEV_(1)、FVC、FEV_(1)/FVC水平,临床上应当进一步推广应用。Objective To investigate the clinical efficacy of moxifloxacin combined with terbutaline on COPD patients and the influence of FEV_(1),FVC and FEV_(1)/FVC.Method 82 patients with chronic obstructive pulmonary disease(COPD)in our hospital from January 2018 to June 2020 were selected and divided into two groups according to different drug use.The control group was treated with moxifloxacin,and the study group was treated with terbutaline and moxifloxacin.The clinical efficacy,FEV_(1),FVC,FEV_(1)/FVC,adverse reactions,quality of life score,blood gas analysis PCT levels were compared between the two groups.Results The clinical efficacy of the study group was better than that of the control group(P<0.05);the FEV_(1),FEV_(1)/FVC and FVC of the study group were higher than those of the control group(P<0.05);the incidence of insomnia,skin itching,nausea and other adverse reactions in the study group were lower than those in the control group(P<0.05);the activity limitation,clinical symptoms and disease effects of the study group were lower than those of the control group(P<0.05);SaO_(2) and PaO_(2) of the study group were higher than those of the control group(P<0.05)The levels of serum PCT in study group were lower than those in control group(P<0.05).Conclusion Moxifloxacin combined with terbutaline can not only effectively improve the clinical efficacy,but also improve the level of FEV_(1),FVC and FEV_(1)/FVC in patients with COPD,which should be further promoted and applied in clinic.

关 键 词：莫西沙星 特布他林 慢性阻塞性肺疾病 临床疗效 FEV_(1) FVC FEV_(1)/FVC 

分 类 号：R563.9[医药卫生—呼吸系统]